Black currant (blackcurrant) trials recruiting now
2 registrations that name black currant as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
RecruitingNCT07365514
Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females
Phase 1
University of Connecticut
About 159 people
Starts Jul 2026 (estimated)
In plain words A Phase 1 study of black currant in female participants 45 to 70, run by University of Connecticut. It plans to enroll about 159 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 45 to 70; healthy volunteers accepted. Conditions: Postmenopausal Osteoporosis; Gut Microbiome; Menopause.
postmenopausal (defined as no more than 10 years since final menstrual cycle) females aged 45-70 years
not on hormone replacement therapy for at least one year before initiation of the study
maintaining normal exercise level (< 7 hours/week) and willing to avoid exercise for 24 hours prior to blood and stool sampling
willing to ingest a dietary blackcurrant supplement or placebo (up to 1,176 mg/day, three 392mg capsules)
3 more inclusion criteria and the exclusion criteria are on the listing.
The goal of this clinical trial is to evaluate the effects of blackcurrant (BC) supplementation on changes in bone density and gut microbiome composition in postmenopausal females.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07859319
Evaluation of the Efficacy and Acceptability of a Phytotherapy Combining Devil's Claw, Blackcurrant and Meadowsweet for the Management of Aromatase Inhibitor-induced Arthralgia in Patients Treated for Localized Breast Cancer in the Adjuvant Setting
Phase 4
Hospices Civils de Lyon
About 105 people
Starts Jan 2027 (estimated)
In plain words A Phase 4 study of black currant in female participants 18 and older, run by Hospices Civils de Lyon. It plans to enroll about 105 people at 3 sites, none in the US.
Common Inclusion Criteria (applicable to both cohorts):
Age 18 years or older.
Histologically or clinically confirmed localized breast cancer treated for at least 3 months with adjuvant hormone therapy according to standard clinical practices: selective estrogen receptor modulators (SERMs, e.g., tamoxifen alone),…
Suffering from hormone therapy-induced arthralgia with a severity score of $\\ge 4/10$ on a numerical rating scale (NRS).
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Phytotherapy Dietary Supplement (Harpagophytum, Meadowsweet, and Blackcurrant); Patient Experience Questionnaire
Registered summary
Adjuvant hormonotherapy is a cornerstone of treatment for localized hormone receptor-positive (HR+) breast cancer, accounting for approximately 80% of patients. The main classes used are selective estrogen receptor modulators (SERMs, including tamoxifen) and aromatase inhibitors (anastrozole, letrozole, exemestane), with or without LH-RH agonists (leuprorelin, goserelin), administered daily for 5 to 8 years. However, these treatments are frequently associated with adverse events, predominantly musculoskeletal disorders such as arthralgia, which can significantly impair quality of life. The full summary is on the listing.